• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pathobiology: journal of immunopathology, molecular and cellular biology >Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer
【24h】

Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer

机译：胃癌成纤维细胞生长因子受体2的表达，异质性及其临床意义

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: We aimed to evaluate the protein and mRNA expression of fibroblast growth factor receptor 2 (FGFR2) by immunohistochemistry (IHC) and mRNA in situ hybridization (ISH), respectively, and to assess the heterogeneity of FGFR2 expression in gastric cancer (GC). Methods: A tissue microarray containing 362 surgically resected GC tissues and 135 matched metastatic lymph nodes was evaluated using FGFR2b IHC and FGFR2 ISH. FGFR2 fluorescence ISH was also performed in 188 cases. Results: All FGFR2-amplified cases (5 of 188) showed FGFR2b protein and FGFR2 mRNA overexpression (p < 0.001), and FGFR2 amplification was not identified in FGFR2b IHC- and FGFR2 mRNA ISH-negative cases. Kaplan-Meier survival analysis revealed that FGFR2b protein and FGFR2 mRNA overexpression was significantly associated with a poor overall survival (p < 0.001 and p = 0.012, respectively), and multivariate analyses showed that FGFR2 nnRNA overexpression was an independent biomarker of a poor overall survival. Intratumoral heterogeneity of FGFR2b protein and FGFR2 mRNA overexpression was observed in 5 of 9 (55.5%) and 18 of 21 (85.7%) cases, respectively. Discordant FGFR2b and FGFR2 expression results between primary and matched metastatic lymph nodes were observed in 5 of 9 (55.5%) and 4 of 14 (28.6%) cases, respectively. Conclusions: Intratumoral heterogeneity and discordant FGFR2b expression in primary tumors and metastatic lymph nodes are common in GC. (C) 2015 S. Karger AG, Basel
机译：背景：我们旨在通过免疫组织化学（IHC）和mRNA原位杂交（ISH）评估成纤维细胞生长因子受体2（FGFR2）的蛋白质和mRNA表达，并评估胃癌（GC）中FGFR2表达的异质性。方法：使用FGFR2b IHC和FGFR2 ISH评估了包含362个手术切除的GC组织和135个匹配的转移性淋巴结的组织微阵列。 188例患者也进行了FGFR2荧光ISH。结果：所有FGFR2扩增病例（188个中的5个）均显示FGFR2b蛋白和FGFR2 mRNA过表达（p <0.001），而在FGFR2b IHC和FGFR2 mRNA ISH阴性病例中未发现FGFR2扩增。 Kaplan-Meier生存分析表明FGFR2b蛋白和FGFR2 mRNA的过表达与总体存活率低显着相关（分别为p <0.001和p = 0.012），多变量分析表明FGFR2 nnRNA的过度表达是总体存活率低的独立生物标志物。 。 FGFR2b蛋白和FGFR2 mRNA过表达的肿瘤内异质性分别在9例中的5例（55.5％）和21例中的18例（85.7％）中观察到。在9例中有5例（55.5％）和14例中有4例（28.6％）观察到原发性和匹配性转移淋巴结之间不一致的FGFR2b和FGFR2表达结果。结论：原发肿瘤和转移性淋巴结中瘤内异质性和不一致的FGFR2b表达在GC中很常见。 （C）2015 S.Karger AG，巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号